Effect of Eszopiclone on Sleep Disturbance & Pain in Cancer - Full Text View

Purpose

To assess the effectiveness of Lunesta on cancer patients who have received a blood or marrow transplant and who require patient controlled analgesia (PCA), specifically to assess whether Lunesta will:

improve sleep thereby decreasing need for opiates via PCA
improve sleep thereby decreasing pain by self report
improve sleep thereby decreasing fatigue by self report

Condition	Intervention	Phase
Sleep Initiation and Maintenance Disorders	Drug: eszopiclone	Phase IV

MedlinePlus related topics:

Cancer Sleep Disorders

ChemIDplus related topics:

Eszopiclone

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title:	Effect of Eszopiclone (Lunesta) on Sleep Disturbance and Pain in Cancer

Further study details as provided by University of California, San Diego:

Primary Outcome Measures:

Patient Self-report data on
sleep,
pain,
fatigue

Secondary Outcome Measures:

opiate dosing from patient controlled analgesia

Estimated Enrollment:	50
Study Start Date:	September 2006
Estimated Study Completion Date:	March 2009

Detailed Description:

Pain and fatigue are the most common symptom complaints of cancer patients. Although dramatic improvements have come about in recognizing and treating cancer related pain, less progress has been made in treating fatigue. Interventions to improve sleep may offer benefit in terms of pain and fatigue.

One of the less commonly recognized side effects of opiate use is sleep disruption.

Experimentally-induced sleep disruption lowers the threshold for detection of painful stimuli. Thus, although opiates are obviously helpful for pain, they do so at certain "costs": they increase next day fatigue, constipation, and have other side effects; they disrupt sleep which further increases next day fatigue; and finally, by virtue of their sleep disruptive properties, they lower the threshold for pain stimuli.

Cancer patients requiring blood/bone marrow transplants (BMT) commonly require PCA because of oral mucositis. The objective of this study is to assess whether opiate usage may be reduced and complaints of fatigue and pain be lessened if patients had better sleep.

Eligibility

Ages Eligible for Study:	20 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female patients hospitalized for blood/bone marrow transplant.
Age 20 - 75
Not currently regularly taking any prescribed sleeping pill more often than 4x/week.
Can tolerate oral medication.

Exclusion Criteria:

Patients with a current history of substance abuse
Patients with a history of allergic response to Lunesta.
Patient who require additional oral or parenteral opioids after starting PCA opioid treatment.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00365261

Locations


United States, California
	UCSD Thornton Hospital	Recruiting
	La Jolla, California, United States, 92037
	Contact: Joel E Dimsdale, MD 619-543-5592 jdimsdale@ucsd.edu
	Principal Investigator: Joel E Dimsdale, MD

Sponsors and Collaborators

University of California, San Diego

Investigators


Principal Investigator:	Joel E Dimsdale, MD	UCSD

More Information

Study ID Numbers:	UCSD 060340, ESRC 054
First Received:	August 15, 2006
Last Updated:	June 3, 2008
ClinicalTrials.gov Identifier:	NCT00365261
Health Authority:	United States: Institutional Review Board

Keywords provided by University of California, San Diego:

pain

fatigue

sleep

bone marrow transplant

cancer

Study placed in the following topic categories:

Sleep Initiation and Maintenance Disorders

Signs and Symptoms

Fatigue

Mental Disorders

Neurologic Manifestations

Dyssomnias

Sleep Disorders

Pain

Sleep Disorders, Intrinsic

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on October 10, 2008

Sponsored by:	University of California, San Diego
Information provided by:	University of California, San Diego
ClinicalTrials.gov Identifier:	NCT00365261